Developmental Therapeutics Program (DTP)

The NCI Developmental Therapeutics Program (DTP) provides critical services and resources to the global academic and private-sector research communities. As part of the National Cancer Institute, DTP plays a central role in advancing the discovery and development of new cancer therapeutic agents by offering access to a broad range of tools, expertise, and preclinical testing services.

DTP supports researchers at every stage of the drug development pipeline, from early-stage screening and mechanistic studies to formulation and toxicology. Through its extensive compound libraries, in vitro and in vivo testing capabilities, and specialized data analysis platforms, DTP empowers scientists to accelerate the transition of promising compounds into potential treatments. These collaborative opportunities are designed to remove barriers and reduce the time and cost associated with traditional drug development.

By fostering innovation and collaboration, DTP aims to bring safe and effective cancer therapies to patients faster. Whether you are an academic investigator with a novel compound or a company seeking to advance a candidate through preclinical development, the DTP is committed to supporting your mission to improve cancer treatment outcomes worldwide.